Novavax (NVAX) closed at $7.47 on November 20, 2026, down 3.2% from the previous close, on volume of 4,489,135 shares (30-day average 6,483,325).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Diagonal Call Spread | 17-Dec-27 : 21-Jan-2812 : 10 C | 1,632 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Moderna 600% YTD rally catches cold: What's next amid stock's downtrend?
Seeking Alpha News (Wed, 18-Nov 12:58 PM ET)
Novavax to Participate in Jefferies London Healthcare Conference
PRNewswire (Wed, 11-Nov 5:00 PM ET)
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
PRNewswire (Thu, 5-Nov 8:00 AM ET)
Market Chameleon (Fri, 30-Oct 3:37 AM ET)
PRNewswire (Thu, 29-Oct 9:38 AM ET)
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
PRNewswire (Thu, 29-Oct 8:00 AM ET)
Novavax to Participate in September Investor Conferences
PRNewswire (Wed, 2-Sep 5:00 PM ET)
PRNewswire (Fri, 28-Aug 8:30 AM ET)
Novavax Lowers Operating Costs, Raises Revenue Outlook as Sanofi Partnership Builds Future Momentum
Market Chameleon (Thu, 6-Aug 4:21 AM ET)
Novavax’s Matrix-M Partnerships Expand to Over 30 Therapeutic Targets Amid Revenue Shift
Market Chameleon (Thu, 7-May 4:20 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of November 20, 2026, NVAX stock price declined to $7.47 with 4,489,135 million shares trading.
NVAX has a beta of 1.75, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.10 to the broad based SPY ETF.
NVAX has a market cap of $1.23 billion. This is considered a Small Cap stock.
Last quarter Novavax reported $68 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.16.
In the last 3 years, NVAX traded as high as $23.86 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): VTI, VB, XBI, IWM, VBK.
NVAX has outperformed the market in the last year with a return of +17.8%, while the SPY ETF gained +5.2%. However, in the most recent history, NVAX shares have underperformed the stock market with its stock returning -15.0% in the last 3 month period and -23.6% for the last 2 week period, while SPY has returned -10.1% and -5.9%, respectively.
NVAX support price is $7.34 and resistance is $8.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX shares will trade within this expected range on the day.